Pfizer Initiates Phase 1 Trial of PF-07799544 and PF-07799933 Combination for BRAF V600-Mutant Solid Tumors, Targeting the Brain-Penetrant Market
Next-Generation Targeted Therapy Combination Surpasses the Blood-Brain Barrier
Pfizer's Phase 1 clinical trial (NCT05538130) of its MEK inhibitor, polfurmetinib (PF-07799544), and BRAF inhibitor, claturafenib (PF-07799933), is now underway. Existing first-generation targeted therapies have been limited by their molecular size and structural constraints, making it difficult for them to cross the blood-brain barrier (BBB) and effectively treat patients with brain metastases. This trial is significant because both compounds are highly engineered, brain-penetrant candidates, offering a completely new treatment option for patients with brain metastases and primary brain tumors, addressing a significant unmet medical need.
Multi-Signal Pathway Blockade Strategy to Overcome Resistance
Conventional single-target therapies have a major limitation: cancer cells rapidly develop resistance by activating alternative signaling pathways. In this Phase 1b trial, polfurmetinib blocks MEK1/2, a downstream component of the MAPK pathway, while claturafenib simultaneously inhibits BRAF monomers and dimers, maximizing synergistic effects. This combination therapy aims to fundamentally block the tumor's evasion mechanisms, significantly delaying the onset of resistance. Furthermore, claturafenib is designed to reduce the paradoxical MAPK activation, a side effect induced by existing treatments.
Competition for Dominance in a $2.2 Billion Market
The current standard of care for BRAF V600-mutant solid tumors is the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) from Novartis. This leading franchise recorded global sales of over $2.215 billion (approximately 3 trillion KRW) in 2025, solidifying its position as the market leader. Pfizer aims to disrupt this market by leveraging the superior brain penetration and broad mutation inhibition capabilities of the polfurmetinib and claturafenib combination, demonstrating a strong commitment to challenging Novartis's dominance.
Global Commercialization and Risk Diversification Strategy
This master clinical trial is a multinational study conducted across global sites in the United States, Australia, Brazil, China, and Japan, involving a total of 124 patients. It includes a diverse basket of indications, such as non-small cell lung cancer (NSCLC), glioblastoma, and thyroid cancer, to simultaneously gather early efficacy data. Pfizer expects to enhance the success rate of subsequent trials and significantly reduce R&D risk by confirming a solid safety profile and intracranial response data early in Phase 1.
This Phase 1 trial is a critical study targeting patients with BRAF V600-mutant solid tumors, which have a high incidence of brain metastases, to obtain superior brain-penetrant data compared to existing approved therapies. In a market dominated by Novartis's Tafinlar and Mekinist combination, which generated $2.215 billion in sales in 2025, Pfizer aims to break the monopoly with its next-generation drugs, polfurmetinib (PF-07799544) and claturafenib (PF-07799933). The initial objective response rate (ORR) and intracranial response data obtained in the dose expansion phase of the Phase 1b trial will serve as a key short-term milestone for determining the go/no-go decision for subsequent trials. In the medium to long term, successful expansion of indications to include difficult-to-treat brain tumors such as glioblastoma and metastatic lung cancer could add a multi-billion dollar blockbuster pipeline to Pfizer's solid tumor portfolio.
Source: ClinicalTrials.gov (api_ct)